Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and... see more

Recent & Breaking News (NDAQ:VRDN)

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

GlobeNewswire November 14, 2022

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

GlobeNewswire November 14, 2022

Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

GlobeNewswire November 8, 2022

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

GlobeNewswire November 8, 2022

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

GlobeNewswire October 22, 2022

Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

GlobeNewswire October 12, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2022

Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters' Option to Purchase Additional Shares in Public Offering

GlobeNewswire August 25, 2022

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

GlobeNewswire August 17, 2022

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

GlobeNewswire August 15, 2022

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

GlobeNewswire August 15, 2022

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

GlobeNewswire August 15, 2022

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

GlobeNewswire August 8, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 5, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 8, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm

Newsfile June 24, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

GlobeNewswire June 23, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm

Accesswire June 18, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact the Firm

Business Wire June 16, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2022